China Opens Up Non-End-To-End Manufacturing Of Biologics Within, Across Border

 
• By Xu Hu
  
New rules shift
China's NMPA launched a pilot program of non-end-to-end manufacturing of certain biologics due at the end of 2026. (Shutterstock)

More from Manufacturing

More from Pink Sheet